Saizen Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Saizen Access in 2026

Growth hormone prescribing has never been simple, but the access landscape for Saizen (Somatropin, EMD Serono) has become increasingly complex. Whether you're managing pediatric patients with growth hormone deficiency or adults with childhood-onset or adult-onset GHD, understanding the current state of Saizen availability is essential for continuity of care.

This briefing covers what you need to know about Saizen supply, insurance dynamics, cost considerations, and the tools available to help your patients maintain uninterrupted therapy.

Shortage Timeline and Current Status

As of early 2026, Saizen is not listed on the FDA's drug shortage database. EMD Serono has not reported formal manufacturing or distribution disruptions.

However, the practical reality for patients is different. Access challenges persist due to:

• Specialty pharmacy distribution: Saizen is not available at standard retail pharmacies and must be dispensed through specialty channels
• Formulary exclusions: Multiple major payers, including select UnitedHealthcare and certain PBM-managed plans, have moved Saizen off preferred formulary tiers or excluded it entirely in favor of Norditropin or Omnitrope
• Prior authorization burden: Virtually all commercial and government plans require prior authorization for somatropin products, with approval processes that can take days to weeks

The broader growth hormone category has not experienced the kind of acute supply disruptions seen with stimulants or GLP-1 agonists, but the structural barriers to access are significant and persistent.

Prescribing Implications

For providers, the key takeaways are:

Formulary Awareness

Before prescribing Saizen, verify your patient's formulary status. An increasing number of plans tier Saizen as non-preferred or exclude it entirely. Prescribing a non-formulary brand can result in:

• Delayed prior authorization or outright denial
• Significantly higher patient copays (often hundreds of dollars per fill)
• Forced therapeutic substitution to a preferred brand

If your patient's plan does not cover Saizen, consider starting with the plan's preferred somatropin product to avoid therapy gaps. The clinical differences between somatropin brands are minimal — all contain the same 191-amino acid recombinant protein.

Prior Authorization Documentation

Strong documentation is critical for approval. Most plans require:

• Confirmed GHD diagnosis through provocative GH stimulation testing (typically two tests)
• Peak GH level below the plan's threshold (commonly ≤10 ng/mL for pediatric, ≤5 ng/mL for adult)
• For pediatric patients: documented growth velocity, bone age assessment, and height below the 3rd or 5th percentile
• For adult patients: documentation of hypothalamic-pituitary disease, surgery, radiation, or childhood-onset GHD with retesting
• Baseline IGF-1 levels

Having this documentation ready before submitting the prior authorization request can significantly reduce turnaround time.

Transition Considerations

When transitioning patients between somatropin brands:

• Dose conversion is generally 1:1 on a mg basis
• Monitor IGF-1 levels 4-6 weeks after switching to confirm therapeutic equivalence
• Provide patient education on the new delivery device (e.g., transitioning from Saizen vials to Norditropin FlexPro pen)
• Update injection training as needed — device mechanics vary across brands

The Availability Picture

Saizen distribution flows through specialty pharmacy networks. Key considerations:

• Retail pharmacies generally do not stock Saizen and cannot readily order it through standard wholesale channels
• Specialty pharmacies affiliated with the patient's PBM or insurer are typically the required dispensing source
• Home delivery is the standard fulfillment model, with cold-chain shipping to maintain product stability
• Regional variation exists — patients in rural areas may face longer delivery windows

Providers who maintain relationships with 2-3 specialty pharmacies can offer patients more flexibility when the designated plan pharmacy has limited stock.

Cost and Access Landscape

Saizen pricing remains substantial:

• 5 mg vial: ~$737-$900 (AWP/cash price)
• 8.8 mg vial: ~$1,150-$1,500
• Monthly therapy cost: $800-$3,000+ depending on dose and weight

For comparison, Omnitrope (biosimilar) typically costs 20-40% less, and some plans offer $0 copay on their preferred somatropin brand.

Patient assistance resources:

• EMD Serono Patient Assistance Program: Provides free Saizen to qualifying uninsured/underinsured patients
• Prescription Hope: Offers Saizen for $70/month through their medication access service
• GoodRx coupons: May reduce cash prices to approximately $287 at select pharmacies
• NeedyMeds and RxAssist: Aggregate additional assistance programs

Tools and Resources for Your Practice

Several tools can streamline the process for both your practice and your patients:

Medfinder for Providers

Medfinder helps identify pharmacies with Saizen in stock, reducing the number of calls your staff needs to make. You can direct patients to check availability at medfinder.com/providers as part of your care coordination workflow.

Prior Authorization Optimization

Consider implementing a standardized GH prior authorization checklist in your practice that includes all commonly required documentation elements. This reduces back-and-forth with insurers and speeds approval.

Patient Education Materials

Share these resources with patients who are struggling to access or afford Saizen:

• How to find Saizen in stock near you
• How to save money on Saizen
• Alternatives to Saizen

Looking Ahead

The growth hormone therapy landscape continues to evolve:

• Long-acting somatropin products like Sogroya (somapacitan, once-weekly) and Skytrofa (lonapegsomatropin, once-weekly) are gaining formulary traction and may reduce the access burden associated with daily injectable products
• Biosimilar competition may increase as additional somatropin biosimilars enter the US market, potentially driving down costs across the category
• PBM formulary consolidation continues to narrow covered options, making formulary awareness an essential part of prescribing decisions

Final Thoughts

Saizen remains a clinically effective somatropin product, but access and affordability challenges require proactive management from prescribers. Staying current on formulary status, maintaining strong prior authorization documentation, and leveraging tools like Medfinder can make a meaningful difference in your patients' ability to access and maintain growth hormone therapy.

For a patient-facing version of this update, share: Saizen shortage update: What patients need to know in 2026.